Sanofi's Lovenox Authorized Generic Could Help Speed Amphastar's Path To Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Availability of an authorized generic since mid-October could make it more difficult for commercial partners Momenta and Sandoz to prove they are likely to suffer irreparable harm unless Amphastar and Watson are enjoined from marketing their generic of the low molecular weight heparin.